Looser Efficacy Standards Could Waste Taxpayer Dollars On Useless Drugs, NEJM Says
Executive Summary
Editorial cites Lilly's failed Alzheimer's candidate solanezumab to argue that looser efficacy standards could result in Medicare paying for ineffective drugs, but it's unlikely that a Scott Gottlieb-led FDA would have approved the drug.